Neogen Chemicals Limited CEO Haridas Kanani, the companys largest shareholder sees 15 percent reduction in holdings value

278865BN9   62.03  2.06  3.21%   
About 62% of 278865BN9's investor base is looking to short. The analysis of the overall prospects from investing in ECL 27 15 DEC 51 suggests that many traders are, at the present time, alarmed. The current market sentiment, together with 278865BN9's historical and current headlines, can help investors time the market. In addition, many technical investors use ECL 27 15 bond news signals to limit their universe of possible portfolio assets.
  
Key Insights Neogen Chemicals significant insider ownership suggests inherent interests in companys expansion 51 percent of...

Read at simplywall.st
Simply Wall St News at Macroaxis
  

ECL 27 15 Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 278865BN9 bond to make a market-neutral strategy. Peer analysis of 278865BN9 could also be used in its relative valuation, which is a method of valuing 278865BN9 by comparing valuation metrics with similar companies.

Peers

278865BN9 Related Equities

Other Information on Investing in 278865BN9 Bond

278865BN9 financial ratios help investors to determine whether 278865BN9 Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 278865BN9 with respect to the benefits of owning 278865BN9 security.